Chronische Niereninsuffizienz Nicht jeder der pinkelt hat auch gesunde Nieren.
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Prevalence of Chronic Kidney Disease in the United States CORESH et al. JAMA 298: 2038 2047, 2007
Kidney disease as a risk factor for the development of cardiovascular disease SARNAK et al. Circulation 108: 2154-2169, 2003
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis McCully Am J Pathol 56: 111-128, 01.07.1969 Mondlandung: 21.07.1969
. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosklerosis McCULLY Am J Pathol 56: 111-128, 1969
The Pathogenesis of Coronary Artery Disease A POSSIBLE ROLE FOR METHIONINE METABOLISM WICLCKEN et al. JCI 57: 1079-1082, 1976
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease HOPE 2 Investigators N Engl J Med 354:1567-77, 2006 5522 patients with vascular disease or or diabetes treated for 5 years vitamin treatment lead substantial reduction in in plasma homocysteine no no significant reduction in in the risk of of myocardial infarction, stroke, or or death from cardiovascular causes
Effect of Homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and ESRD JAMISON et al. JAMA 298(10):1163-1170, 2007 2056 pts pts median follow-up: 3.2 3.2 years 26 26 % lowering Hcy (folic acid vitamin B6 B6 and and vitamin B12)
The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. ARNADOTTIR et al. Scand J Clin Lab Invest 56(1):41-6, 1996
Two cardiovascular risk factors in one? Homocysteine and its correlation to GFR A meta-analysis of 41 studies with 27,000 participants KIELSTEIN et al. Kidney Blood Pres Res, 2008
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. McIntyre et al. C J Am Soc Nephrol. 3(1):19-26, 2008 PET with H 15 2 O or 13 NH 3 is the only technique that allows the noninvasive measurement of regional absolute (ml/min/g) myocardial blood flow
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. McIntyre et al. C J Am Soc Nephrol. 3(1):19-26, 2008
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. McIntyre et al. C J Am Soc Nephrol. 3(1):19-26, 2008
Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. SELBY et al. Am J Kidney Dis. 47(5):830-41, 2006
Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. SELBY et al. Am J Kidney Dis. 47(5):830-41, 2006
Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. SELBY et al. C J Am Soc Nephrol. 1(6):1216-25, 2006
Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. SELBY et al. C J Am Soc Nephrol. 1(6):1216-25, 2006
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Quality of care and outcomes among patients (n=17,785) with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. PATEL et al. Am Heart J 156(4):674-81, 2008 15,560 patients from 137 hospitals 2/3 had CKD!!!!!!!! 43.9% 14.2% 6.6% moderate CKD severe CKD kidney failure
Quality of care and outcomes among patients (n=17,785) with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. PATEL et al. Am Heart J 156(4):674-81, 2008
Quality of care and outcomes among patients (n=17,785) with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. PATEL et al. Am Heart J 156(4):674-81, 2008
Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. PATEL et al. Am Heart J 156(4):674-81, 2008
Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. PATEL et al. Am Heart J 156(4):674-81, 2008
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. SUZUKI et al. AJKD 52(3):501-6, 2008 Losartan 50 mg/d Candesartan 8 mg/d Valsartan of 80 mg/d
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. SUZUKI et al. AJKD 52(3):501-6, 2008
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. SUZUKI et al. AJKD 52(3):501-6, 2008
Chronische Niereninsufizienz 1) 1) Was hat sich nicht geändert? 2) 2) Was hat sich geändert? 3) 3) Was könnte sich ändern? 4) 4) Was muss sich ändern 5) 5) Zusammenfassung
Zusammenfassung